Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 790 | 1,434 | 279 | 208 | 603 |
| Gross Profit | 790 | 1,434 | 279 | 208 | 603 |
| Operating Expenses | 3,351 | 7,634 | 6,443 | 7,263 | 5,406 |
| Operating Income | -2,561 | -6,201 | -6,163 | -7,055 | -4,803 |
| Interest Expense | 2 | 52 | 5 | 38 | 15 |
| Other Income | 371 | 775 | -3,687 | -830 | 3,867 |
| Pre-tax Income | -2,192 | -5,478 | -9,856 | -7,923 | -951 |
| Net Income Continuous | -2,192 | -5,478 | -9,856 | -7,923 | -951 |
| Minority Interests | -4 | 12 | -22 | -26 | 0 |
| Net Income | $-2,188 | $-5,490 | $-9,834 | $-7,897 | $-951 |
| EPS Basic Total Ops | -31.18 | -100.30 | -923.24 | -846.93 | -219.79 |
| EPS Basic Continuous Ops | -31.18 | -136.95 | -917.76 | -836.53 | -125.06 |
| EPS Diluted Total Ops | -31.18 | -100.30 | -923.24 | -846.93 | -219.79 |
| EPS Diluted Continuous Ops | -31.18 | -136.95 | -917.76 | -836.53 | -125.06 |
| EBITDA(a) | $-2,561 | $-6,201 | $-6,163 | $-7,055 | $-4,803 |